30% of Young Cancer Patients Use Cannabis To Relieve Symptoms

August 26, 2019August 26, 2019Big Pharma

Total74
72
2
0
Like

Share via

A new study found that 30% of young adult cancer patients use cannabis as a natural plant medicine to relieve symptoms of mainstream treatments.

Cannabis can help alleviate some of the symptoms of cancer and its treatment, and a new study examines the prevalence of its use among young adult cancer patients now that medical cannabis is becoming increasingly available.

The demographic and clinical factors likely to correlate with cannabis use and differences in moderate to severe symptoms between users and non-users are reported in a study published in Journal of Adolescent and Young Adult Oncology (JAYAO), a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

Click here to read the full-text article free on the Journal of Adolescent and Young Adult Oncology (JAYAO) website through September 26, 2019.

Exit & Build Land Summit IV - Online And In Person

Kristine Donovan, PhD, MBA and colleagues from Moffitt Cancer Center, Tampa, FL coauthored the article entitled “Cannabis Use in Young Adult Cancer Patients.” On urine drug testing for a breakdown product of cannabis, they showed that 30% of young adult cancer patients ages 18 to 39 tested positive.

Widget not in any sidebars

The researchers report that this prevalence rate of cannabis use is higher than for young adults in the general population and adult cancer patients seeking specialized symptom management.

Young adult cannabis users were more likely to be male and, surprisingly, to report having more severe symptoms, including pain, nausea, lack of appetite, constipation, and difficulty sleeping.

Editor-in-Chief of JAYAO Leonard S. Sender, MD, CHOC Children’s Hospital Hyundai Cancer Institute, Orange, CA, states: “As cannabis becomes legal for medical and recreational use in more states, it is increasingly important that its use in cancer patients is evidence-based. More research is needed into premorbidity and effectiveness relative to other pharmacological agents.”

Source:
LiebertPub